Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication of the Extract of the Unaudited Financial Results of the Company for the Quarter ended June 30, 2025 in "Business Standard" and "Makkal Kural" on August 14, 2025.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals has published the extract of its unaudited financial results for Q1 FY26 (quarter ended June 30, 2025) in Business Standard and Makkal Kural on August 14, 2025. Total income from operations stood at Rs. 3,462.40 lakhs, up modestly from Rs. 3,328.63 lakhs in the same quarter last year but lower than Rs. 3,906.00 lakhs in the preceding quarter (Q4 FY25). Net profit after tax came in at Rs. 332.27 lakhs, a sharp turnaround from a loss of Rs. 71.45 lakhs in Q1 FY25 and also higher than Rs. 109.86 lakhs in Q4 FY25. Basic and diluted EPS for the quarter stood at Rs. 1.43, compared to a loss of Rs. 0.31 per share a year ago. The results were approved by the Board and reviewed by the Audit Committee on August 12, 2025.
The year-on-year swing from a loss to a healthy profit is a positive signal for shareholders, indicating improved operating performance. The sequential dip in revenue, however, suggests some quarter-on-quarter softness that investors may want to track. Overall, the strong earnings recovery should be viewed favorably for the stock.